|
| 36602784 | Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. | JAMA Oncol | 2023 |
| 37590404 | Current Concepts in Patellar Tendinopathy: An Overview of Imaging, Pathogenesis, and Nonoperative and Operative Management. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37211044 | Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. | | 2023 |
| 37142539 | Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. | | 2023 |
| 36576009 | HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. | J Natl Cancer Inst | 2023 |
| 36563600 | Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. | | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37188177 | HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer. | | 2023 |
| 37120452 | Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. | | 2023 |
| 36859416 | Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. | Nat Commun | 2023 |
| 35144055 | Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. | Cancer Treat Rev | 2022 |
| 36008651 | Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. | Breast Cancer Research and Treatment | 2022 |
| 35436729 | Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment? | | 2022 |
| 35427175 | Posterior Leg Pain: Understanding Soleus Muscle Injuries. | Radiographics | 2022 |
| 36067616 | Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. | European Journal of Cancer | 2022 |
| 36200668 | SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of mRNA. | Future Oncology | 2022 |
| 34051058 | Gene expression profiles of breast cancer metastasis according to organ site. | Molecular Oncology | 2022 |
| 34990895 | Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. | EBioMedicine | 2022 |
| 34824288 | Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. | NPJ Breast Cancer | 2021 |
| 33968735 | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. | Frontiers in Oncology | 2021 |
| 33742063 | Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. | npj Precision Oncology | 2021 |
| 33632929 | Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. | Clinical Cancer Research | 2021 |
| 33536433 | Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. | npj Breast Cancer | 2021 |
| 34161883 | Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. | eBioMedicine | 2021 |
| 33785053 | RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. | Breast Cancer Research | 2021 |
| 33397968 | Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. | npj Breast Cancer | 2021 |
| 31037288 | HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. | J Natl Cancer Inst | 2020 |
| 31959756 | Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. | Nature Communications | 2020 |
| 31838010 | Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. | Lancet Oncology, The | 2020 |
| 32404150 | Frequency and spectrum of PIK3CA somatic mutations in breast cancer. | Breast Cancer Research | 2020 |
| 32000054 | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. | | 2020 |
| 33152285 | A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. | Lancet Oncol | 2020 |
| 32578279 | Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). | European Journal of Cancer Care | 2020 |
| 32633563 | SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. | Future Oncology | 2020 |
| 32962980 | A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. | Clin Cancer Res | 2020 |
| 32674482 | mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. | Cancers | 2020 |
| 32938620 | Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. | Clinical Cancer Research | 2020 |
| 30710068 | Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. | Oncologist | 2019 |
| 31750258 | Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. | Frontiers in Oncology | 2019 |
| 35100699 | Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. | JCO Precision Oncology | 2019 |
| 30621698 | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. | BMC Medicine | 2019 |
| 30922362 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. | Journal for ImmunoTherapy of Cancer | 2019 |
| 31023863 | A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. | Oncologist | 2019 |
| 30679318 | Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. | Oncologist | 2019 |
| 31106144 | A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. | Frontiers in Oncology | 2019 |
| 30778520 | De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. | Annals of Oncology | 2019 |
| 31533777 | Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. | Breast Cancer Research | 2019 |
| 29763779 | Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. | | 2018 |
| 29045543 | A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. | Annals of Oncology | 2018 |